Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Apr;79(11-12):1736–1741. doi: 10.1038/sj.bjc.6690276

Prognostic value of nuclear morphometry in patients with TNM stage T1 ovarian clear cell adenocarcinoma

C Q Liu 1, H Sasaki 1, M T Fahey 2, A Sakamoto 3, S Sato 4, T Tanaka 1
PMCID: PMC2362809  PMID: 10206285

Abstract

In 40 patients with TNM stage T1 ovarian clear cell adenocarcinoma, we used nuclear morphometry to study the relations among morphometric variables, clinical prognostic factors and outcome. The presence of one or more giant nuclear cells was positively associated with death (OR = 10.6, P = 0.02) and tended to be associated with disease recurrence (OR = 5.1, P = 0.07). Nuclear irregularity (expressed in terms of the nuclear roundness factor) was positively associated with both death (OR = 8.6, P = 0.02) and disease recurrence (OR = 8.2, P = 0.02). A combination of giant nuclear cell presence or nuclear irregularity proved to be a useful prognostic indicator, with a sensitivity and specificity of 83% and 71% in the prediction of death, and 75% and 71% in the prediction of disease recurrence. Patients' age and substage were of no prognostic value. We conclude that the nuclear morphometric characteristics, especially the presence of giant nuclear cells and nuclear irregularity, may be useful in predicting outcome in patients with early stage ovarian clear cell adenocarcinoma. © 1999 Cancer Research Campaign

Keywords: ovarian clear cell adenocarcinoma, nuclear morphometry, TMN stage T1, prognosis, lymphatic involvement

Full Text

The Full Text of this article is available as a PDF (88.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baak J. P., Schipper N. W., Wisse-Brekelmans E. C., Ceelen T., Bosman F. T., van Geuns H., Wils J. The prognostic value of morphometrical features and cellular DNA content in cis-platin treated late ovarian cancer patients. Br J Cancer. 1988 May;57(5):503–508. doi: 10.1038/bjc.1988.114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Borland R. N., Partin A. W., Epstein J. I., Brendler C. B. The use of nuclear morphometry in predicting recurrence of transitional cell carcinoma. J Urol. 1993 Feb;149(2):272–275. doi: 10.1016/s0022-5347(17)36053-6. [DOI] [PubMed] [Google Scholar]
  3. Christopherson W. M., Alberhasky R. C., Connelly P. J. Carcinoma of the endometrium: I. A clinicopathologic study of clear-cell carcinoma and secretory carcinoma. Cancer. 1982 Apr 15;49(8):1511–1523. doi: 10.1002/1097-0142(19820415)49:8<1511::aid-cncr2820490802>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  4. Colombel M., De Launoit Y., Bellot J., Kiss R., Abbou C., Chopin D. Prognostic evaluation of morphonuclear parameters in superficial and invasive bladder cancer. Br J Urol. 1995 Mar;75(3):364–369. doi: 10.1111/j.1464-410x.1995.tb07350.x. [DOI] [PubMed] [Google Scholar]
  5. Dembo A. J., Davy M., Stenwig A. E., Berle E. J., Bush R. S., Kjorstad K. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol. 1990 Feb;75(2):263–273. [PubMed] [Google Scholar]
  6. Diamond D. A., Berry S. J., Jewett H. J., Eggleston J. C., Coffey D. S. A new method to assess metastatic potential of human prostate cancer: relative nuclear roundness. J Urol. 1982 Oct;128(4):729–734. doi: 10.1016/s0022-5347(17)53158-4. [DOI] [PubMed] [Google Scholar]
  7. Finn C. B., Luesley D. M., Buxton E. J., Blackledge G. R., Kelly K., Dunn J. A., Wilson S. Is stage I epithelial ovarian cancer overtreated both surgically and systemically? Results of a five-year cancer registry review. Br J Obstet Gynaecol. 1992 Jan;99(1):54–58. doi: 10.1111/j.1471-0528.1992.tb14393.x. [DOI] [PubMed] [Google Scholar]
  8. Fuhrman S. A., Lasky L. C., Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982 Oct;6(7):655–663. doi: 10.1097/00000478-198210000-00007. [DOI] [PubMed] [Google Scholar]
  9. Fukuzawa S., Hashimura T., Sasaki M., Yamabe H., Yoshida O. Nuclear morphometry for improved prediction of the prognosis of human bladder carcinoma. Cancer. 1995 Nov 15;76(10):1790–1796. doi: 10.1002/1097-0142(19951115)76:10<1790::aid-cncr2820761017>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  10. Goff B. A., Sainz de la Cuesta R., Muntz H. G., Fleischhacker D., Ek M., Rice L. W., Nikrui N., Tamimi H. K., Cain J. M., Greer B. E. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol. 1996 Mar;60(3):412–417. doi: 10.1006/gyno.1996.0065. [DOI] [PubMed] [Google Scholar]
  11. Haapasalo H., Atkin N. B., Collan Y., Pesonen E., Paljärvi L. Tumour ploidy, morphometry, histological grading and clinical features in ovarian carcinoma: mutual relations. Anal Cell Pathol. 1991 Sep;3(5):261–271. [PubMed] [Google Scholar]
  12. Haapasalo H., Collan Y., Seppä A., Gidlund A. L., Atkin N. B., Pesonen E. Prognostic value of ovarian carcinoma grading methods--a method comparison study. Histopathology. 1990 Jan;16(1):1–7. doi: 10.1111/j.1365-2559.1990.tb01053.x. [DOI] [PubMed] [Google Scholar]
  13. Jenison E. L., Montag A. G., Griffiths C. T., Welch W. R., Lavin P. T., Greer J., Knapp R. C. Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma. Gynecol Oncol. 1989 Jan;32(1):65–71. doi: 10.1016/0090-8258(89)90852-4. [DOI] [PubMed] [Google Scholar]
  14. Kennedy A. W., Biscotti C. V., Hart W. R., Tuason L. J. Histologic correlates of progression-free interval and survival in ovarian clear cell adenocarcinoma. Gynecol Oncol. 1993 Sep;50(3):334–338. doi: 10.1006/gyno.1993.1221. [DOI] [PubMed] [Google Scholar]
  15. Kennedy A. W., Biscotti C. V., Hart W. R., Webster K. D. Ovarian clear cell adenocarcinoma. Gynecol Oncol. 1989 Mar;32(3):342–349. doi: 10.1016/0090-8258(89)90637-9. [DOI] [PubMed] [Google Scholar]
  16. Miller B. E., Lavia L. A., Horbelt D. V. The prognostic value of image analysis in ovarian cancer. Cancer. 1991 Mar 1;67(5):1318–1321. doi: 10.1002/1097-0142(19910301)67:5<1318::aid-cncr2820670508>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  17. Montag A. G., Jenison E. L., Griffiths C. T., Welch W. R., Lavin P. T., Knapp R. C. Ovarian clear cell carcinoma. A clinicopathologic analysis of 44 cases. Int J Gynecol Pathol. 1989;8(2):85–96. doi: 10.1097/00004347-198906000-00001. [DOI] [PubMed] [Google Scholar]
  18. Nativ O., Sabo E., Raviv G., Medalia O., Moskovitz B., Goldwasser B. The role of nuclear morphometry for predicting disease outcome in patients with localized renal cell carcinoma. Cancer. 1995 Oct 15;76(8):1440–1444. doi: 10.1002/1097-0142(19951015)76:8<1440::aid-cncr2820760822>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  19. O'Brien M. E., Schofield J. B., Tan S., Fryatt I., Fisher C., Wiltshaw E. Clear cell epithelial ovarian cancer (mesonephroid): bad prognosis only in early stages. Gynecol Oncol. 1993 May;49(2):250–254. doi: 10.1006/gyno.1993.1117. [DOI] [PubMed] [Google Scholar]
  20. Partin A. W., Walsh A. C., Pitcock R. V., Mohler J. L., Epstein J. I., Coffey D. S. A comparison of nuclear morphometry and Gleason grade as a predictor of prognosis in stage A2 prostate cancer: a critical analysis. J Urol. 1989 Nov;142(5):1254–1258. doi: 10.1016/s0022-5347(17)39049-3. [DOI] [PubMed] [Google Scholar]
  21. Petru E., Lahousen M., Tamussino K., Pickel H., Stranzl H., Stettner H., Winter R. Lymphadenectomy in stage I ovarian cancer. Am J Obstet Gynecol. 1994 Feb;170(2):656–662. doi: 10.1016/s0002-9378(94)70244-6. [DOI] [PubMed] [Google Scholar]
  22. Pound C. R., Partin A. W., Epstein J. I., Simons J. W., Marshall F. F. Nuclear morphometry accurately predicts recurrence in clinically localized renal cell carcinoma. Urology. 1993 Sep;42(3):243–248. doi: 10.1016/0090-4295(93)90611-d. [DOI] [PubMed] [Google Scholar]
  23. Rodenburg C. J., Cornelisse C. J., Hermans J., Fleuren G. J. DNA flow cytometry and morphometry as prognostic indicators in advanced ovarian cancer: a step forward in predicting the clinical outcome. Gynecol Oncol. 1988 Feb;29(2):176–187. doi: 10.1016/0090-8258(88)90212-0. [DOI] [PubMed] [Google Scholar]
  24. Sharkey F. E., Pavlak R. J., Greiner A. S. Morphometric analysis of differentiation in human breast carcinoma. Tumor grading. Arch Pathol Lab Med. 1983 Aug;107(8):406–410. [PubMed] [Google Scholar]
  25. Wagner T. M., Adler A., Sevelda P., Assmann I., Knepflé C. F., Czerwenka K., Heinzl H., Ploem-Zaaijer J. J. Prognostic significance of cell DNA content in early-stage ovarian cancer (FIGO stages I and II/A) by means of automatic image cytometry. Int J Cancer. 1994 Jan 15;56(2):167–172. doi: 10.1002/ijc.2910560203. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES